The estimated Net Worth of Patrick F. Kelly is at least $2.79 Миллион dollars as of 13 April 2022. Dr Kelly owns over 15,000 units of Forma Therapeutics stock worth over $2,098,729 and over the last 4 years he sold FMTX stock worth over $51,296. In addition, he makes $636,581 as Sr. VP & Chief Medical Officer at Forma Therapeutics.
Dr has made over 3 trades of the Forma Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 15,000 units of FMTX stock worth $75,750 on 13 April 2022.
The largest trade he's ever made was selling 64,288 units of Forma Therapeutics stock on 23 June 2020 worth over $1,286,403. On average, Dr trades about 14,089 units every 110 days since 2020. As of 13 April 2022 he still owns at least 104,884 units of Forma Therapeutics stock.
You can see the complete history of Dr Kelly stock trades at the bottom of the page.
Dr. Patrick F. Kelly M.D. is the Sr. VP & Chief Medical Officer at Forma Therapeutics.
As the Sr. VP & Chief Medical Officer of Forma Therapeutics, the total compensation of Dr D at Forma Therapeutics is $636,581. There are 1 executives at Forma Therapeutics getting paid more, with Frank D. Lee having the highest compensation of $963,198.
Dr D is 56, he's been the Sr. VP & Chief Medical Officer of Forma Therapeutics since . There are 4 older and 3 younger executives at Forma Therapeutics. The oldest executive at Forma Therapeutics Holdings, Inc., is Dr. David N. Cook Ph.D., 63, who is the Sr. VP & Chief Scientific Officer.
Patrick's mailing address filed with the SEC is C/O FORMA THERAPEUTICS HOLDINGS, INC., 300 NORTH BEACON STREET, SUITE 501, WATERTOWN, MA, 02472.
Over the last 4 years, insiders at Forma Therapeutics have traded over $446,330 worth of Forma Therapeutics stock and bought 9,000,000 units worth $180,000,000 . The most active insiders traders include Capital Management, L.P.Ra ..., Peter Kolchinsky и Capital Management, L.P.Ra .... On average, Forma Therapeutics executives and independent directors trade stock every 37 days with the average trade being worth of $10,575,905. The most recent stock trade was executed by Patrick F. Kelly on 13 April 2022, trading 15,000 units of FMTX stock currently worth $75,750.
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts.
Forma Therapeutics executives and other stock owners filed with the SEC include: